speb/financial-data huggingface dataset:
CURA.TO balance_sheet (quarterly, 2025-09-30) — Non Current Note Receivables: 2908000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Non Current Prepaid Assets: 10456000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Normalized EBITDA: 59883000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Normalized Income: -51372340.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Notes Receivable: 2778000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: 48438000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Operating Gains Losses: 3606000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Operating Income: 4031000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Operating Revenue: 320244000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 255475630.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 27231000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Other Current Borrowings: 43693000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 16015000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Other Equity Adjustments: -2210000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Other Gand A: 18463000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Other Income Expense: -3125000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Other Intangible Assets: 1033428000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Other Investments: 1373000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Other Non Cash Items: 2068000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 1290000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Other Non Current Liabilities: 209787000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: 1329000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Other Operating Expenses: 3690000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Other Payable: 9547000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Other Properties: 363682000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Other Receivables: 4381000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Other Special Charges: -199000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Payables: 96129000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Payables And Accrued Expenses: 178848000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Pretax Income: -24308000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Proceeds From Stock Option Exercised: 203000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Properties: 0.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Purchase Of Business: 0.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Purchase Of Intangibles: -35000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Purchase Of Investment: 0.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Purchase Of PPE: -16557000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Raw Materials: 61822000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Receivables: 71922000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Receivables Adjustments Allowances: -2612000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 141370000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 54372000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Rent And Landing Fees: 15596000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Rent Expense Supplemental: 15596000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Repayment Of Debt: -28840000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Research And Development: 261000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Restricted Cash: 14700000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Retained Earnings: -1527427000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Salaries And Wages: 67798000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Sale Of Business: 0.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Sale Of PPE: 451000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Selling And Marketing Expense: 12346000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Selling General And Administration: 116520000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Share Issued: 255475630.00
CURA.TO income_statement (quarterly, 2025-09-30) — Special Income Charges: -1870000.00
CURA.TO cash_flow (quarterly, 2025-09-30) — Stock Based Compensation: 10294000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 814824000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: -853599000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: -935340.00
CURA.TO income_statement (quarterly, 2025-09-30) — Tax Provision: 30238000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.21
CURA.TO balance_sheet (quarterly, 2025-09-30) — Total Assets: 2883304000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 1314788000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Total Debt: 823374000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 886230000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Total Expenses: 316213000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 1997074000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 2443256000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 1698040000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Total Operating Income As Reported: 4031000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Total Tax Payable: 32566000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Total Unusual Items: -4454000.00
CURA.TO income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: -4454000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Tradeand Other Payables Non Current: 510219000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Work In Process: 61960000.00
CURA.TO balance_sheet (quarterly, 2025-09-30) — Working Capital: 141014000.00
CURA.TO income_statement (annual, 2025-12-31) — +Operating Expense: 605572000.00
CURA.TO income_statement (quarterly, 2025-12-31) — +Operating Expense: 153246000.00
CURA.TO income_statement (annual, 2025-12-31) — +Total Revenue: 1268135000.00
CURA.TO income_statement (quarterly, 2025-12-31) — +Total Revenue: 323364000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Accounts Payable: 74725000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 74725000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Accounts Receivable: 73864000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Accounts Receivable: 73864000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Accumulated Depreciation: -488597000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Accumulated Depreciation: -488597000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Additional Paid In Capital: 2345402000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 2345402000.00
CURA.TO cash_flow (annual, 2025-12-31) — Asset Impairment Charge: 9080000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Asset Impairment Charge: 4375000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Assets Held For Sale Current: 3681000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Assets Held For Sale Current: 3681000.00
CURA.TO income_statement (annual, 2025-12-31) — Basic Average Shares: 254030316.00
CURA.TO income_statement (annual, 2025-12-31) — Basic EPS: -1.05
CURA.TO cash_flow (annual, 2025-12-31) — Beginning Cash Position: 107226000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 107488000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Buildings And Improvements: 548388000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Buildings And Improvements: 548388000.00
CURA.TO cash_flow (annual, 2025-12-31) — Capital Expenditure: -64649000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Capital Expenditure: -16368000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Capital Lease Obligations: 278313000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Capital Lease Obligations: 278313000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Capital Stock: 0.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Capital Stock: 0.00
CURA.TO balance_sheet (annual, 2025-12-31) — Cash And Cash Equivalents: 89173000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 89173000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 89173000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 89173000.00
CURA.TO cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Financing Activities: -73493000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Financing Activities: -28942000.00
CURA.TO cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Investing Activities: -69198000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Investing Activities: -18162000.00
CURA.TO cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Operating Activities: 152025000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: 48035000.00
CURA.TO cash_flow (annual, 2025-12-31) — Cash From Discontinued Financing Activities: 0.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Cash From Discontinued Financing Activities: 0.00
CURA.TO cash_flow (annual, 2025-12-31) — Cash From Discontinued Investing Activities: -1146000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Cash From Discontinued Investing Activities: -1146000.00
CURA.TO cash_flow (annual, 2025-12-31) — Cash From Discontinued Operating Activities: -14319000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Cash From Discontinued Operating Activities: -5712000.00
CURA.TO cash_flow (annual, 2025-12-31) — Change In Account Payable: -5197000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Change In Account Payable: 20766000.00
CURA.TO cash_flow (annual, 2025-12-31) — Change In Accrued Expense: 147915000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Change In Accrued Expense: 22459000.00
CURA.TO cash_flow (annual, 2025-12-31) — Change In Inventory: -3724000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Change In Inventory: 844000.00
CURA.TO cash_flow (annual, 2025-12-31) — Change In Other Current Assets: 1380000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Change In Other Current Assets: 286000.00
CURA.TO cash_flow (annual, 2025-12-31) — Change In Other Current Liabilities: -17875000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Change In Other Current Liabilities: -4665000.00
CURA.TO cash_flow (annual, 2025-12-31) — Change In Payable: -5197000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Change In Payable: 20766000.00
CURA.TO cash_flow (annual, 2025-12-31) — Change In Payables And Accrued Expense: 142718000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Change In Payables And Accrued Expense: 43225000.00
CURA.TO cash_flow (annual, 2025-12-31) — Change In Prepaid Assets: -8811000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Change In Prepaid Assets: -10438000.00
CURA.TO cash_flow (annual, 2025-12-31) — Change In Receivables: 6699000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Change In Receivables: 5283000.00
CURA.TO cash_flow (annual, 2025-12-31) — Change In Working Capital: 120387000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Change In Working Capital: 34535000.00
CURA.TO cash_flow (annual, 2025-12-31) — Changes In Account Receivables: -10961000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Changes In Account Receivables: -8072000.00
CURA.TO cash_flow (annual, 2025-12-31) — Changes In Cash: -6131000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Changes In Cash: -5927000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Common Stock: 0.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Common Stock: 0.00
CURA.TO balance_sheet (annual, 2025-12-31) — Common Stock Equity: 756350000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 756350000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Construction In Progress: 22618000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Construction In Progress: 22618000.00
CURA.TO income_statement (annual, 2025-12-31) — Cost Of Revenue: 637113000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 159810000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Current Accrued Expenses: 91292000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Current Accrued Expenses: 91292000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Current Assets: 448623000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Current Assets: 448623000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Current Capital Lease Obligation: 31521000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Current Capital Lease Obligation: 31521000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Current Debt: 35730000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Current Debt: 35730000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Current Debt And Capital Lease Obligation: 67251000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Current Debt And Capital Lease Obligation: 67251000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Current Deferred Liabilities: 3600000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Current Deferred Liabilities: 3600000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Current Deferred Revenue: 634000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Current Deferred Revenue: 634000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Current Liabilities: 294314000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 294314000.00
CURA.TO cash_flow (annual, 2025-12-31) — Deferred Income Tax: -34089000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Deferred Income Tax: -17002000.00
CURA.TO cash_flow (annual, 2025-12-31) — Deferred Tax: -34089000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Deferred Tax: -17002000.00
CURA.TO cash_flow (annual, 2025-12-31) — Depreciation: 216042000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Depreciation: 52673000.00
CURA.TO cash_flow (annual, 2025-12-31) — Depreciation Amortization Depletion: 216042000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Depreciation Amortization Depletion: 52673000.00
CURA.TO income_statement (annual, 2025-12-31) — Depreciation Amortization Depletion Income Statement: 141394000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Depreciation Amortization Depletion Income Statement: 35141000.00
CURA.TO cash_flow (annual, 2025-12-31) — Depreciation And Amortization: 216042000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Depreciation And Amortization: 52673000.00
CURA.TO income_statement (annual, 2025-12-31) — Depreciation And Amortization In Income Statement: 141394000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 35141000.00
CURA.TO income_statement (annual, 2025-12-31) — Diluted Average Shares: 262480130.00
CURA.TO income_statement (annual, 2025-12-31) — Diluted EPS: -1.05
CURA.TO income_statement (annual, 2025-12-31) — Diluted NI Availto Com Stockholders: -273364000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: -102111000.00
CURA.TO cash_flow (annual, 2025-12-31) — Dividends Received Cfi: 225000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Dividends Received Cfi: 60000.00
CURA.TO income_statement (annual, 2025-12-31) — EBIT: 22615000.00
CURA.TO income_statement (quarterly, 2025-12-31) — EBIT: 7753000.00
CURA.TO income_statement (annual, 2025-12-31) — EBITDA: 238657000.00
CURA.TO income_statement (quarterly, 2025-12-31) — EBITDA: 60426000.00
CURA.TO income_statement (annual, 2025-12-31) — Earnings From Equity Interest Net Of Tax: -42294000.00
CURA.TO cash_flow (annual, 2025-12-31) — Effect Of Exchange Rate Changes: 478000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Effect Of Exchange Rate Changes: 12000.00
CURA.TO cash_flow (annual, 2025-12-31) — End Cash Position: 101573000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — End Cash Position: 101573000.00
CURA.TO cash_flow (annual, 2025-12-31) — Financing Cash Flow: -73493000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Financing Cash Flow: -28942000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Finished Goods: 98112000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Finished Goods: 98112000.00
CURA.TO cash_flow (annual, 2025-12-31) — Free Cash Flow: 73057000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Free Cash Flow: 25955000.00
CURA.TO cash_flow (annual, 2025-12-31) — Gain Loss On Investment Securities: 343000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Gain Loss On Investment Securities: -750000.00
CURA.TO income_statement (annual, 2025-12-31) — Gain On Sale Of Ppe: -3049000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Gain On Sale Of Ppe: -499000.00
CURA.TO income_statement (annual, 2025-12-31) — Gain On Sale Of Security: 3343000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Gain On Sale Of Security: 672000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: -1808000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: -1808000.00
CURA.TO income_statement (annual, 2025-12-31) — General And Administrative Expense: 412382000.00
CURA.TO income_statement (quarterly, 2025-12-31) — General And Administrative Expense: 107830000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Goodwill: 635117000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Goodwill: 635117000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Goodwill And Other Intangible Assets: 1646232000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Goodwill And Other Intangible Assets: 1646232000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Gross PPE: 1219856000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Gross PPE: 1219856000.00
CURA.TO income_statement (annual, 2025-12-31) — Gross Profit: 631022000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Gross Profit: 163554000.00
CURA.TO income_statement (annual, 2025-12-31) — Impairment Of Capital Assets: 9080000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Impairment Of Capital Assets: 5746000.00
CURA.TO cash_flow (annual, 2025-12-31) — Income Tax Paid Supplemental Data: 27058000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Income Tax Paid Supplemental Data: -369000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Income Tax Payable: 18952000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Income Tax Payable: 18952000.00
CURA.TO income_statement (annual, 2025-12-31) — Insurance And Claims: 9528000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Insurance And Claims: 2531000.00
CURA.TO income_statement (annual, 2025-12-31) — Interest Expense: 100829000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Interest Expense: 24498000.00
CURA.TO income_statement (annual, 2025-12-31) — Interest Expense Non Operating: 100829000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 24498000.00
CURA.TO income_statement (annual, 2025-12-31) — Interest Income: 663000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Interest Income: 174000.00
CURA.TO income_statement (annual, 2025-12-31) — Interest Income Non Operating: 663000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Interest Income Non Operating: 174000.00
CURA.TO cash_flow (annual, 2025-12-31) — Interest Paid Supplemental Data: 103606000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Interest Paid Supplemental Data: 34733000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Interest Payable: 1704000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Interest Payable: 1704000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Inventory: 225022000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Inventory: 225022000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Invested Capital: 1305002000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Invested Capital: 1305002000.00
CURA.TO cash_flow (annual, 2025-12-31) — Investing Cash Flow: -70344000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Investing Cash Flow: -19308000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Investments And Advances: 263000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Investments And Advances: 263000.00
CURA.TO cash_flow (annual, 2025-12-31) — Issuance Of Debt: 83190000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Issuance Of Debt: 43661000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Land And Improvements: 12937000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Land And Improvements: 12937000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Long Term Capital Lease Obligation: 246792000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Long Term Capital Lease Obligation: 246792000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Long Term Debt: 512922000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Long Term Debt: 512922000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 759714000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 759714000.00
CURA.TO cash_flow (annual, 2025-12-31) — Long Term Debt Issuance: 83190000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Long Term Debt Issuance: 43661000.00
CURA.TO cash_flow (annual, 2025-12-31) — Long Term Debt Payments: -117355000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Long Term Debt Payments: -46646000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Long Term Equity Investment: 263000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Long Term Equity Investment: 263000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Machinery Furniture Equipment: 270066000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Machinery Furniture Equipment: 270066000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Minority Interest: 83931000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Minority Interest: 83931000.00
CURA.TO income_statement (annual, 2025-12-31) — Minority Interests: -2917000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Minority Interests: -2200000.00
CURA.TO cash_flow (annual, 2025-12-31) — Net Business Purchase And Sale: -542000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Net Business Purchase And Sale: 0.00
CURA.TO balance_sheet (annual, 2025-12-31) — Net Debt: 459479000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Net Debt: 459479000.00
CURA.TO cash_flow (annual, 2025-12-31) — Net Foreign Currency Exchange Gain Loss: -3686000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Net Foreign Currency Exchange Gain Loss: 78000.00
CURA.TO income_statement (annual, 2025-12-31) — Net Income: -273364000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Net Income: -102111000.00
CURA.TO income_statement (annual, 2025-12-31) — Net Income Common Stockholders: -273364000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: -102111000.00
CURA.TO income_statement (annual, 2025-12-31) — Net Income Continuous Operations: -244197000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: -84254000.00
CURA.TO income_statement (annual, 2025-12-31) — Net Income Discontinuous Operations: -26250000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Net Income Discontinuous Operations: -15657000.00
CURA.TO income_statement (annual, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -273364000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -102111000.00
CURA.TO income_statement (annual, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -247114000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -86454000.00
CURA.TO cash_flow (annual, 2025-12-31) — Net Income From Continuing Operations: -201903000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Net Income From Continuing Operations: -41960000.00
CURA.TO income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: -270447000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: -99911000.00
CURA.TO cash_flow (annual, 2025-12-31) — Net Intangibles Purchase And Sale: -1209000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Net Intangibles Purchase And Sale: -789000.00
CURA.TO income_statement (annual, 2025-12-31) — Net Interest Income: -100166000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Net Interest Income: -24324000.00
CURA.TO cash_flow (annual, 2025-12-31) — Net Investment Purchase And Sale: -173000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Net Investment Purchase And Sale: 114000.00
CURA.TO cash_flow (annual, 2025-12-31) — Net Issuance Payments Of Debt: -34165000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Net Issuance Payments Of Debt: -2985000.00
CURA.TO cash_flow (annual, 2025-12-31) — Net Long Term Debt Issuance: -34165000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Net Long Term Debt Issuance: -2985000.00
CURA.TO income_statement (annual, 2025-12-31) — Net Non Operating Interest Income Expense: -100166000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -24324000.00
CURA.TO cash_flow (annual, 2025-12-31) — Net Other Financing Charges: -39584000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Net Other Financing Charges: -26000000.00
CURA.TO cash_flow (annual, 2025-12-31) — Net Other Investing Changes: -4746000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Net Other Investing Changes: -1959000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Net PPE: 731259000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Net PPE: 731259000.00
CURA.TO cash_flow (annual, 2025-12-31) — Net PPE Purchase And Sale: -62753000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Net PPE Purchase And Sale: -15588000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Net Tangible Assets: -889882000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: -889882000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Non Current Accounts Receivable: 2382000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Non Current Accounts Receivable: 2382000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Non Current Deferred Assets: 443000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Assets: 443000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Non Current Deferred Liabilities: 212002000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Liabilities: 212002000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Assets: 443000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Assets: 443000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Liabilities: 212002000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Liabilities: 212002000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Non Current Note Receivables: 2980000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Non Current Note Receivables: 2980000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Non Current Prepaid Assets: 11082000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Non Current Prepaid Assets: 11082000.00
CURA.TO income_statement (annual, 2025-12-31) — Normalized EBITDA: 245758000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 65999000.00
CURA.TO income_statement (annual, 2025-12-31) — Normalized Income: -241504210.00
CURA.TO income_statement (quarterly, 2025-12-31) — Normalized Income: -82051330.00
CURA.TO balance_sheet (annual, 2025-12-31) — Notes Receivable: 4629000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Notes Receivable: 4629000.00
CURA.TO cash_flow (annual, 2025-12-31) — Operating Cash Flow: 137706000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: 42323000.00
CURA.TO cash_flow (annual, 2025-12-31) — Operating Gains Losses: -1979000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Operating Gains Losses: -173000.00
CURA.TO income_statement (annual, 2025-12-31) — Operating Income: 25450000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Operating Income: 10308000.00
CURA.TO income_statement (annual, 2025-12-31) — Operating Revenue: 1268135000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Operating Revenue: 323364000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 257491582.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 257491582.00
CURA.TO balance_sheet (annual, 2025-12-31) — Other Current Assets: 37379000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Other Current Assets: 37379000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Other Current Borrowings: 35730000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Other Current Borrowings: 35730000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Other Current Liabilities: 19927000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Other Current Liabilities: 19927000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Other Equity Adjustments: -1808000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Other Equity Adjustments: -1808000.00
CURA.TO income_statement (annual, 2025-12-31) — Other Gand A: 76893000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Other Gand A: 20756000.00
CURA.TO income_statement (annual, 2025-12-31) — Other Income Expense: -3498000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Other Income Expense: -2729000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Other Intangible Assets: 1011115000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Other Intangible Assets: 1011115000.00
CURA.TO cash_flow (annual, 2025-12-31) — Other Non Cash Items: 6241000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Other Non Cash Items: 736000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Other Non Current Assets: 2051000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Other Non Current Assets: 2051000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Other Non Current Liabilities: 207496000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Other Non Current Liabilities: 207496000.00
CURA.TO income_statement (annual, 2025-12-31) — Other Non Operating Income Expenses: 3603000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 2844000.00
CURA.TO income_statement (annual, 2025-12-31) — Other Operating Expenses: 5299000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 111000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Other Payable: 4986000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Other Payable: 4986000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Other Properties: 365847000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Other Properties: 365847000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Other Receivables: 5092000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Other Receivables: 5092000.00
CURA.TO income_statement (annual, 2025-12-31) — Other Special Charges: -1685000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Other Special Charges: 0.00
CURA.TO balance_sheet (annual, 2025-12-31) — Payables: 112244000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Payables: 112244000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Payables And Accrued Expenses: 203536000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 203536000.00
CURA.TO income_statement (annual, 2025-12-31) — Pretax Income: -78214000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Pretax Income: -16745000.00
CURA.TO cash_flow (annual, 2025-12-31) — Proceeds From Stock Option Exercised: 256000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Proceeds From Stock Option Exercised: 43000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Properties: 0.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Properties: 0.00
CURA.TO cash_flow (annual, 2025-12-31) — Provisionand Write Offof Assets: 2510000.00
CURA.TO cash_flow (annual, 2025-12-31) — Purchase Of Business: -542000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Purchase Of Business: 0.00
CURA.TO cash_flow (annual, 2025-12-31) — Purchase Of Intangibles: -1209000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Purchase Of Intangibles: -789000.00
CURA.TO cash_flow (annual, 2025-12-31) — Purchase Of Investment: -173000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Purchase Of Investment: 114000.00
CURA.TO cash_flow (annual, 2025-12-31) — Purchase Of PPE: -63440000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Purchase Of PPE: -15579000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Raw Materials: 58914000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Raw Materials: 58914000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Receivables: 80968000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Receivables: 80968000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Receivables Adjustments Allowances: -2617000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Receivables Adjustments Allowances: -2617000.00
CURA.TO income_statement (annual, 2025-12-31) — Reconciled Cost Of Revenue: 562465000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 142278000.00
CURA.TO income_statement (annual, 2025-12-31) — Reconciled Depreciation: 216042000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 52673000.00
CURA.TO income_statement (annual, 2025-12-31) — Rent And Landing Fees: 59314000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Rent And Landing Fees: 13738000.00
CURA.TO income_statement (annual, 2025-12-31) — Rent Expense Supplemental: 59314000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Rent Expense Supplemental: 13738000.00
CURA.TO cash_flow (annual, 2025-12-31) — Repayment Of Debt: -117355000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Repayment Of Debt: -46646000.00
CURA.TO income_statement (annual, 2025-12-31) — Research And Development: 805000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Research And Development: -48000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Restricted Cash: 12400000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Restricted Cash: 12400000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Retained Earnings: -1587244000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Retained Earnings: -1587244000.00
CURA.TO income_statement (annual, 2025-12-31) — Salaries And Wages: 266647000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Salaries And Wages: 70805000.00
CURA.TO cash_flow (annual, 2025-12-31) — Sale Of Business: 0.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Sale Of Business: 0.00
CURA.TO cash_flow (annual, 2025-12-31) — Sale Of PPE: 687000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Sale Of PPE: -9000.00
CURA.TO income_statement (annual, 2025-12-31) — Selling And Marketing Expense: 45692000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Selling And Marketing Expense: 10212000.00
CURA.TO income_statement (annual, 2025-12-31) — Selling General And Administration: 458074000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Selling General And Administration: 118042000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Share Issued: 257491582.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Share Issued: 257491582.00
CURA.TO income_statement (annual, 2025-12-31) — Special Income Charges: -10444000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Special Income Charges: -6245000.00
CURA.TO cash_flow (annual, 2025-12-31) — Stock Based Compensation: 35736000.00
CURA.TO cash_flow (quarterly, 2025-12-31) — Stock Based Compensation: 12341000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Stockholders Equity: 756350000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 756350000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Tangible Book Value: -889882000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: -889882000.00
CURA.TO income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: -1491210.00
CURA.TO income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: -1170330.00
CURA.TO income_statement (annual, 2025-12-31) — Tax Provision: 123689000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Tax Provision: 25215000.00
CURA.TO income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.21
CURA.TO income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.21
CURA.TO balance_sheet (annual, 2025-12-31) — Total Assets: 2845315000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Total Assets: 2845315000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Total Capitalization: 1269272000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 1269272000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Total Debt: 826965000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Total Debt: 826965000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: 840281000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 840281000.00
CURA.TO income_statement (annual, 2025-12-31) — Total Expenses: 1242685000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Total Expenses: 313056000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 2005034000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 2005034000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Total Non Current Assets: 2396692000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 2396692000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 1710720000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 1710720000.00
CURA.TO income_statement (annual, 2025-12-31) — Total Operating Income As Reported: 25450000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Total Operating Income As Reported: 10308000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Total Tax Payable: 32533000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Total Tax Payable: 32533000.00
CURA.TO income_statement (annual, 2025-12-31) — Total Unusual Items: -7101000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Total Unusual Items: -5573000.00
CURA.TO income_statement (annual, 2025-12-31) — Total Unusual Items Excluding Goodwill: -7101000.00
CURA.TO income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: -5573000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Tradeand Other Payables Non Current: 531508000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Tradeand Other Payables Non Current: 531508000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Work In Process: 67996000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Work In Process: 67996000.00
CURA.TO balance_sheet (annual, 2025-12-31) — Working Capital: 154309000.00
CURA.TO balance_sheet (quarterly, 2025-12-31) — Working Capital: 154309000.00
CURA.TO income_statement (quarterly, 2026-03-31) — +Operating Expense: 156537000.00
CURA.TO income_statement (quarterly, 2026-03-31) — +Total Revenue: 324231000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 76100000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 70660000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Accumulated Depreciation: -492134000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 2348719000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Asset Impairment Charge: 0.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Assets Held For Sale Current: 3054000.00
CURA.TO income_statement (quarterly, 2026-03-31) — Basic Average Shares: 258476410.00
CURA.TO income_statement (quarterly, 2026-03-31) — Basic EPS: 0.27
CURA.TO cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 101573000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Buildings And Improvements: 553285000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Capital Expenditure: -17046000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 268023000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Capital Stock: 0.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 106129000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 106129000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Financing Activities: 297000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Investing Activities: -16586000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Operating Activities: 21271000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Cash From Discontinued Financing Activities: 0.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Cash From Discontinued Investing Activities: 0.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Cash From Discontinued Operating Activities: -283000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Change In Account Payable: 1659000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Change In Accrued Expense: -15046000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Change In Income Tax Payable: -89478000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Change In Inventory: -16281000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Change In Other Current Assets: 375000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Change In Other Current Liabilities: -4991000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Change In Payable: -87819000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Change In Payables And Accrued Expense: -102865000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Change In Prepaid Assets: 5247000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Change In Receivables: 4186000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Change In Tax Payable: -89478000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Change In Working Capital: -114329000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Changes In Account Receivables: 4186000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Changes In Cash: 4699000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Common Stock: 0.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 821112000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Construction In Progress: 23788000.00
CURA.TO income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 166941000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Current Accrued Expenses: 83743000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Current Assets: 461516000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 32755000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Current Debt: 40014000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 72769000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Current Deferred Liabilities: 3288000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Current Deferred Revenue: 1117000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 296342000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Deferred Income Tax: -6982000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Deferred Tax: -6982000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Depreciation: 52706000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Depreciation Amortization Depletion: 52706000.00
CURA.TO income_statement (quarterly, 2026-03-31) — Depreciation Amortization Depletion Income Statement: 33667000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Depreciation And Amortization: 52706000.00
CURA.TO income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 33667000.00
CURA.TO income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 263888023.00
CURA.TO income_statement (quarterly, 2026-03-31) — Diluted EPS: 0.27
CURA.TO income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 69799000.00
CURA.TO income_statement (quarterly, 2026-03-31) — EBIT: -3102000.00
CURA.TO income_statement (quarterly, 2026-03-31) — EBITDA: 49604000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Effect Of Exchange Rate Changes: -143000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — End Cash Position: 106129000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Financing Cash Flow: 297000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Finished Goods: 113861000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Free Cash Flow: 3942000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Gain Loss On Investment Securities: -342000.00
CURA.TO income_statement (quarterly, 2026-03-31) — Gain On Sale Of Ppe: 194000.00
CURA.TO income_statement (quarterly, 2026-03-31) — Gain On Sale Of Security: -1205000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Gains Losses Not Affecting Retained Earnings: -10162000.00
CURA.TO income_statement (quarterly, 2026-03-31) — General And Administrative Expense: 110681000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Goodwill: 633524000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 1615585000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Gross PPE: 1205080000.00
CURA.TO income_statement (quarterly, 2026-03-31) — Gross Profit: 157290000.00
CURA.TO income_statement (quarterly, 2026-03-31) — Impairment Of Capital Assets: 0.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Income Tax Paid Supplemental Data: 1511000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Income Tax Payable: 21661000.00
CURA.TO income_statement (quarterly, 2026-03-31) — Insurance And Claims: 2395000.00
CURA.TO income_statement (quarterly, 2026-03-31) — Interest Expense: 25527000.00
CURA.TO income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 25527000.00
CURA.TO income_statement (quarterly, 2026-03-31) — Interest Income: 212000.00
CURA.TO income_statement (quarterly, 2026-03-31) — Interest Income Non Operating: 212000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Interest Paid Supplemental Data: 22204000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Interest Payable: 6794000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Inventory: 241284000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Invested Capital: 1386203000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Investing Cash Flow: -16586000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Investments And Advances: 342000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Issuance Of Debt: 362978000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Land And Improvements: 12937000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 235268000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 525077000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 760345000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Long Term Debt Issuance: 362978000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Long Term Debt Payments: -347112000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Long Term Equity Investment: 342000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Machinery Furniture Equipment: 250027000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Minority Interest: 87997000.00
CURA.TO income_statement (quarterly, 2026-03-31) — Minority Interests: 16000.00
CURA.TO balance_sheet (quarterly, 2026-03-31) — Net Debt: 458962000.00
CURA.TO cash_flow (quarterly, 2026-03-31) — Net Foreign Currency Exchange Gain Loss: 1547000.00
CURA.TO income_statement (quarterly, 2026-03-31) — Net Income: 69799000.00
CURA.TO income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 69799000.00
CURA.TO income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 70076000.00
CURA.TO income_statement (quarterly, 2026-03-31) — Net Income Discontinuous Operations: -293000.00
CURA.TO income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 69799000.00